biotech
Novartis Invests $150M in Monte Rosa’s Molecular Glue Technology for Autoimmune Diseases
Novartis, Monte Rosa, Molecular Glue, Protein Degradation, Autoimmune Diseases, MRT-6160, VAV1-degrader, Biotech Collaboration
Ottimo Pharma Emerges with David Epstein at Helm, Focusing on Novel PD1/VEGFR2 Bi-Functional Antibody
Ottimo Pharma, David Epstein, PD1/VEGFR2 bi-functional antibody, Cancer immunotherapy, VEGF bifunctional antibody, Biotech startup
AvenCell Therapeutics Secures $112 Million Series B Funding for Revolutionary ‘Switchable’ CAR-T Cell Therapy
AvenCell Therapeutics, Series B Funding, CAR-T Cell Therapy, Switchable CAR-Ts, Clinical Trials, Biotech Innovation
Lundbeck Strengthens Neuro-Rare Disease Portfolio with $2.6 Billion Acquisition of Longboard Pharmaceuticals
Lundbeck, Longboard Pharmaceuticals, Neuro-Rare Diseases, Acquisition, Biotech, Pharmaceutical Industry
Kurma Partners Secures €140M for Biofund IV, Aiming for €250M to Fuel European Healthcare Innovation
Kurma Partners, Biofund IV, Healthcare Innovation, Venture Capital, European Biotech, Healthcare Investment
Bristol Myers Squibb Invests $110 Million in T-Cell Therapy Pact with Prime Medicine
Bristol Myers Squibb (BMS), Prime Medicine, T-cell therapy, Ex vivo therapies, Biotech investment, Pharmaceutical partnerships
Upstream Biotech Prepares to Join the Wave of Biotech IPOs with Inflammation-Focused Therapies
Biotech IPOs, Upstream Biotech, Inflammation-focused therapies, Biotechnology industry, Public offerings, Healthcare innovation
IO Biotech’s IO102-IO103 Vaccine in Combination with Keytruda Shows Promising Results in Phase 2 Trial for Advanced Squamous Cell Carcinoma of the Head and Neck
IO Biotech, IO102-IO103, Keytruda (pembrolizumab), Phase 2 trial, Squamous cell carcinoma of the head and neck (SCCHN), Cancer vaccine, Immunotherapy
ESMO 2024: IO Biotech’s IO102-IO103 Vaccine in Combination with Pembrolizumab Shows Promising Results in Head and Neck Cancer
IO Biotech, IO102-IO103, Pembrolizumab (Keytruda), Head and Neck Cancer, ESMO Congress 2024, Therapeutic Cancer Vaccine, Immunotherapy
Biotech IPO Market Sees Rare Upsurge with Triple Listing Success
Biotech IPO, Market Flux, Tripleheader, Bicara Therapeutics, Zenas BioPharma, MBX Biosciences, Stock Surge, Pharmaceutical Industry